Delos Capital logo

Delos Capital

North America, New York, United States, New York

Description

Delos Capital is a New York-based private equity firm with a dedicated focus on the lower-middle market. The firm specializes in making control investments in established companies, typically partnering closely with existing management teams to drive growth and operational improvements. Their investment strategy is centered on identifying businesses with strong fundamentals that can benefit from strategic guidance and capital infusion, aiming to create significant long-term value.

The firm targets companies across a range of sectors, including industrials, chemicals, packaging, and business services. Delos Capital seeks out businesses with enterprise values generally ranging from $25 million to $250 million. Within these transactions, their typical equity investment per deal falls between $10 million and $50 million, reflecting their commitment to significant ownership stakes and active involvement in their portfolio companies. This approach allows them to implement comprehensive operational enhancements and pursue strategic growth initiatives.

Delos Capital's value creation strategy extends beyond just capital provision. They leverage their team's extensive industry experience and operational expertise to support management in areas such as market expansion, product development, and efficiency optimization. By focusing on fundamental business improvements and sustainable growth, Delos Capital aims to transform their portfolio companies into stronger, more competitive entities within their respective markets, ultimately generating attractive returns for their investors.

Investor Profile

Delos Capital has backed more than 25 startups, with 2 new investments in the last 12 months alone. The firm has led 8 rounds, about 32% of its total and boasts 5 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series B, Series A, Series C rounds (top funding stages).
  • Majority of deals are located in United States, Germany, Canada.
  • Strong thematic focus on Health Care, Biotechnology, Medical.
  • Typical check size: $10M – $50M.

Stage Focus

  • Series B (28%)
  • Series A (24%)
  • Series C (20%)
  • Private Equity (12%)
  • Series D (8%)
  • Debt Financing (4%)
  • Series E (4%)

Country Focus

  • United States (92%)
  • Germany (4%)
  • Canada (4%)

Industry Focus

  • Health Care
  • Biotechnology
  • Medical
  • Medical Device
  • Pharmaceutical
  • Therapeutics
  • Oncology
  • Health Diagnostics
  • Manufacturing
  • Biopharma
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Delos Capital frequently co-invest with?

Boehringer Ingelheim Venture Fund
Europe, Rheinland-Pfalz, Germany, Ingelheim Am Rhein
Co-Investments: 4
SG
North America, Massachusetts, United States, Stoneham
Co-Investments: 3
New Enterprise Associates
North America, California, United States, Menlo Park
Co-Investments: 6
Bain Capital Life Sciences
North America, Massachusetts, United States, Boston
Co-Investments: 3
Lumira Ventures
North America, Ontario, Canada, Toronto
Co-Investments: 4
Longitude Capital
North America, California, United States, Menlo Park
Co-Investments: 3
Ascension Ventures
North America, Missouri, United States, Clarkton
Co-Investments: 4
Rock Springs Capital
North America, Maryland, United States, Baltimore
Co-Investments: 3
Quan Capital
Asia, Shanghai, China, Shanghai
Co-Investments: 3
AV
North America, California, United States, San Francisco
Co-Investments: 3

Which angels does Delos Capital often collaborate with?

NB
Europe, Basel-Stadt, Switzerland, Basel
Shared Deals: 1
RD
North America, New York, United States
Shared Deals: 1

What are some of recent deals done by Delos Capital?

Avenzo Therapeutics

San Diego, California, United States

Avenzo Therapeutics specializes in the development of oncology therapies for cancer treatment.

BiotechnologyHealth CareMedicalOncologyTherapeutics
Series ANov 18, 2024
Alpha9 Theranostics

Vancouver, British Columbia, Canada

Alpha9 Theranostics is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies.

BiotechnologyMedicalProduct Research
Series COct 23, 2024
Amount Raised: $175,000,000
Cardurion Pharmaceuticals

Boston, Massachusetts, United States

Cardurion is a cardiovascular biotechnology company developing therapeutics for the treatment of heart failure and cardiovascular diseases.

BiotechnologyHealth CareMedicalPharmaceutical
Series BJul 16, 2024
Amount Raised: $260,000,000
AltruBio

Los Altos, California, United States

AltruBio is focused on developing targeted antibody therapeutics for the treatment of cancer and immune related inflammatory diseases.

BiotechnologyHealth CareMedical
Series BMay 21, 2024
Amount Raised: $225,000,000
Zenas BioPharma

Waltham, Massachusetts, United States

Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients.

BiopharmaHealth CarePharmaceutical
Series CMay 7, 2024
Amount Raised: $200,000,000
Avenzo Therapeutics

San Diego, California, United States

Avenzo Therapeutics specializes in the development of oncology therapies for cancer treatment.

BiotechnologyHealth CareMedicalOncologyTherapeutics
Series AMar 26, 2024
Amount Raised: $150,000,000
Instylla

Waltham, Massachusetts, United States

Instylla is a medical equipment supplier that provides liquid embolics of the next generation for interventional radiology.

BiotechnologyCommercialMedical Device
Series CAug 15, 2023
Amount Raised: $30,000,000
Ensoma

Boston, Massachusetts, United States

Ensomaa is a genomic medicine company that develops on one-time in vivo treatments for immuno-oncology and other therapeutic applications.

BiotechnologyGeneticsLife ScienceMedicalOncologyTherapeutics
Series BMay 16, 2023
Amount Raised: $50,000,000
Rejoni

Bedford, Massachusetts, United States

Rejoni develops solutions designed to minimize the short and long-term risks associated with gynecological procedures.

BiotechnologyHealth CareHealth DiagnosticsMedical Device
Series BDec 7, 2022
Amount Raised: $26,250,000
Rgenta Therapeutics

Cambridge, Massachusetts, United States

Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology.

BiotechnologyHealth CareMedicalOncologyPharmaceuticalTherapeutics
Series ANov 29, 2022
Amount Raised: $52,000,000